Viramune Print Ad Cited By FDA For Risk Minimization
This article was originally published in The Pink Sheet Daily
Executive Summary
Boxed text providing risk information for the HIV therapy uses print that is too small and omits necessary statements, FDA's ad division says. Boehringer Ingelheim must present FDA with a plan to discontinue using the ad by Oct. 6.
You may also be interested in...
FDA Warning Letter Snuffs Out Boehringer's Atrovent/Combivent Ads
The ad, which features birthday candles being blown out, makes unsubstantiated effectiveness claims, an FDA warning letter states. Boehringer Ingelheim said the ad is no longer in use; the company plans to distribute corrective information.
FDA Warning Letter Snuffs Out Boehringer's Atrovent/Combivent Ads
The ad, which features birthday candles being blown out, makes unsubstantiated effectiveness claims, an FDA warning letter states. Boehringer Ingelheim said the ad is no longer in use; the company plans to distribute corrective information.
Viramune Labeling Revision Warns Of Hepatic Failure In High-Risk Population
High-risk women taking the HIV agent should be closely monitored for hepatotoxicity during the first 18 weeks of treatment, a "Dear Doctor" letter states.